Published in Blood on May 01, 2013
Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell (2014) 1.79
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature (2014) 1.55
Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Front Oncol (2014) 0.93
Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. Oncotarget (2016) 0.91
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov (2016) 0.88
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia (2016) 0.82
K-Ras protein as a drug target. J Mol Med (Berl) (2016) 0.80
KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Rep (2016) 0.79
KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nat Commun (2016) 0.77
Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Blood (2016) 0.76
Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo. Leukemia (2015) 0.76
Modeling of RAS complexes supports roles in cancer for less studied partners. BMC Biophys (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res (2008) 54.83
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
The guanine nucleotide-binding switch in three dimensions. Science (2001) 9.34
Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 8.47
Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell (1997) 6.55
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Multiple Ras functions can contribute to mammalian cell transformation. Cell (1995) 5.24
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell (2000) 3.68
The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature (1995) 3.61
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A (2012) 3.21
Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell (2005) 2.39
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res (2009) 2.30
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett (2008) 2.28
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood (2008) 2.10
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal (2011) 1.77
GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta (2002) 1.74
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet (2009) 1.71
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol (2009) 1.67
Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol (2007) 1.41
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther (2011) 1.33
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2010) 1.25
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood (2011) 1.08
Differentiated functions expressed by cultured mouse lymphoma cells. I. Specificity and kinetics of cell responses to corticosteroids. Exp Cell Res (1970) 1.07
KRAS mutation profile in colorectal carcinoma and novel mutation--internal tandem duplication in KRAS. Pol J Pathol (2008) 1.07
Different structural requirements within the switch II region of the Ras protein for interactions with specific downstream targets. Oncogene (1995) 0.95
Oncogenic Ras-induced morphologic change is through MEK/ERK signaling pathway to downregulate Stat3 at a posttranslational level in NIH3T3 cells. Neoplasia (2008) 0.90
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
A critical assessment of Mus musculus gene function prediction using integrated genomic evidence. Genome Biol (2008) 4.78
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell (2008) 4.06
The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Bypassing a kinase activity with an ATP-competitive drug. Science (2003) 3.71
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Acute lymphoblastic leukaemia. Lancet (2013) 3.44
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell (2002) 3.41
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2003) 2.76
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72
Selective amygdalohippocampectomy versus anterior temporal lobectomy in the management of mesial temporal lobe epilepsy: a meta-analysis of comparative studies. J Neurosurg (2013) 2.71
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res (2008) 2.57
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42